Brain tumor imaging and cancer management: The neuro-oncologists perspective

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 2, 2006, Pages 127-136

  Newton, Herbert B ^a,b   Ray Chaudhury, Abhik ^a   Cavaliere, Robert ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Dardinger Neuro Oncology Center   (United States)

Author keywords

Brain tumors; Diffusion imaging; Gliomas; Magnetic resonance spectroscopy; MRI; Neuroimaging; Perfusion imaging

Indexed keywords

ANTIINFECTIVE AGENT; BROXURIDINE; CARBOPLATIN; CARMUSTINE; LOMUSTINE; PROCARBAZINE; VATALANIB; VINCRISTINE;

BRAIN ABSCESS; BRAIN INFARCTION; BRAIN NECROSIS; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; EVALUATION; GLIOMA; HUMAN; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; ONCOLOGY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; WORLD HEALTH ORGANIZATION;

BRAIN ABSCESS; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEUROSURGICAL PROCEDURES; PATIENT CARE PLANNING;

EID: 33845999914     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e31802bb571     Document Type: Review

References (82)

1. Newton HB. Primary brain tumors: review of etiology, diagnosis, and treatment. Am Fam Phys. 1994;49:787-797.
2. Preston-Martin S. Epidemiology of primary CNS neoplasms. Neurol Clin. 1996;14:273-290.
3. Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther. 2001;1:395-401.
4. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol. 2002;4:278-299.
5. Hess KR, Broglio DR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293-2299.
6. Newton HB. Neurological complications of systemic cancer. Am Fam Phys. 1999;59:878-886.
7. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91:1382-1390.
8. Ricci PE. Imaging of adult brain tumors. Neuroimaging Clin N Am. 1999;9:651-669.
9. Nelson SJ. Imaging of brain tumors after therapy. Neuroimaging Clin N Am. 1999;9:801-819.
10. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx. 2005;2:333-347.
11. Henson JW, Gaviani P, Gonzalez RG. MRI in the treatment of adult gliomas. Lancet Oncol. 2005;6:167-175.
12. Young RJ, Sills AK, Brem S, et al. Neuroimaging of metastatic brain disease. Neurosurg. 2005;57(suppl 5):S10-S23.
13. Sorensen AG. Magnetic resonance as a cancer imaging biomarker. J Clin Oncol. 2006;24:3274-3281.
14. Rees J. Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol. 2003;16:643-650.
15. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-225.
16. Mariani L, Siegenthaler P, Guzman R, et al. The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas. Acta Neurochir (Wien). 2004;146:441-448.
17. Barker FG, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance - nonenhancing supratentorial cerebral tumors. Cancer. 1997;80:936-941.
18. Nguyen JB, Black BR, Leimkuehler MM, et al. Intracranial pyogenic abscess: imaging diagnosis utilizing recent advances in computed tomography and magnetic resonance imaging. Crit Rev Comput Tomogr. 2004;45:181-224.
19. Lai PH, Hsu SS, Lo YK, et al. Role of diffusion-weighted imaging and proton MR spectroscopy in distinguishing between pyogenic brain abscess and necrotic brain tumor. Acta Neurol Taiwan. 2004;13:107-113.
20. Chang SC, Lai PH, Chen WL, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors. Comparison with conventional MRI. Clin Imaging. 2002;26:227-236.
21. Ferreira NP, Otta GM, do Amaral LL, et al. Imaging aspects of pyogenic infections of the central nervous system. Top Magn Reson Imaging. 2005;16:145-154.
22. Enzinger C, Strasser-Fuchs S, Ropele S, et al. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging. Mult Scler. 2005;11:135-139.
23. Castillo M, Kwock L, Scatliff J, et al. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am. 1998;6:1-20.
24. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2:497-507.
25. Murphy M, Loosemore A, Clifton AG, et al. The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg. 2002;16:329-334.
26. Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol. 1999;45:69-81.
27. Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated gliomas. Neurosurgery. 2001;49:823-829.
28. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998.
29. Hollingworth W, Medina LS, Lenkinski RE, et al. A systematic review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006;27:1404-1411.
30. Ishimaru H, Morikawa M, Iwanaga S, et al. Differentiation between high-grade glioma and brain tumor using single-voxel proton MR spectroscopy. Eur Radiol. 2001;11:1784-1791.
31. Kremer S, Grand S, Remy C, et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol. 2002;29:105-113.
32. Kremer S, Grand S, Berger F, et al. Dynamic contrast-enhanced MRI: differentiating melanoma and renal carcinoma metastases from high-grade astrocytomas and other metastases. Neuroradiology. 2003;45:44-49.
33. Hartmann M, Heiland S, Harting I, et al. Distinguishing primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett. 2003;338:119-122.
34. Witwer BP, Moftakhar R, Hasan KM, et al. Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. J Neurosurg. 2002;97:568-575.
35. Price SJ, Burnet NG, Donovan T, et al. Diffusion tensor imaging of brain tumours at 3T: a potential tool for assessing white matter tract invasion. Clin Radiol. 2003;58:455-462.
36. Panigrahy A, Krieger MD, Gonzalez-Gomez I, et al. Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol. 2006;27:560-572.
37. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast enhanced T2-weighted imaging. Radiology. 1999;211:791-798.
38. Roberts HC, Roberts TPL, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899.
39. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746-755.
40. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. ANJR Am J Neuroradiol. 2006;27:859-867.
41. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol. 2004;25:214-221.
42. Hobbs SK, Shi G, Homer R, et al. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging. 2003;18:530-536.
43. Vlieger EJ, Maroie CB, Leenstra S, et al. Functional magnetic resonance imaging for neurosurgical planning in neurooncology. Eur Radiol. 2004;14:1143-1153.
44. Lemole GM, Henn JS, Riina HA, et al. Cranial application of frameless stereotaxy. BNI Q. 2001;17:16-24.
45. Nimsky C, Ganslandt O, Kober H, et al. Intraoperative magnetic resonance imaging combined with neuronavigation: a new concept. Neurosurgery. 2001;48:1082-1091.
46. Ren A, Gao P, Sun Y. Correlation of MR imaging and histopathology after partial resection of normal rabbit brain. Chin Med J. 2002;115:247-253.
47. Khan RB, Gutin PH, Rai SN, et al. Use of diffusion weighted magnetic resonance imaging in predicting early postoperative outcome in new neurological deficits after brain tumor resection. Neurosurgery. 2006;59:60-66.
48. Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2001;50:915-928.
49. Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59:126-137.
50. Raza SM, Pradilla G, Legnani FG, et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther. 2005;5:477-494.
51. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite radiation therapy system) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg. 2003;99:297-303.
52. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54:479-487.
53. Matheus MG, Castillo M, Ewend M, et al. CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience. AJNR Am J Neuroradiol. 2004;25:1211-1217.
54. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol. 2005;73:57-69.
55. Mardor Y, Rahav O, Zauberman Y, et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 2005;65:6858-6863.
56. Lidar Z, Mardor Y, Jones T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472-479.
57. Vos MJ, Uitdehaag BMJ, Barkhof F, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology. 2003;60:826-830.
58. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19:551-557.
59. Warren KE, Patronas N, Aiken AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst. 2001;93:1401-1405.
60. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
61. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004;58:1147-1152.
62. Grant R, Liang BC, Slattery J, et al. Chemotherapy response criteria in malignant glioma. Neurology. 1997;48:1336-1340.
63. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. 1997;3:1457-1466.
64. Chenevert TL, Stegman LD, Taylor JMG, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029-2036.
65. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100.
66. Hein PA, Eskey CJ, Dunn JF, et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol. 2004;25:201-209.
67. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239:632-649.
68. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH, and angiogenesis. Expert Rev Anticancer Ther. 2004;4:105-128.
69. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging. 2002;15:233-240.
70. Provenzale JM, Galvez Moya MO, Leeds NE, et al. MR imaging assessment of the effects of a novel anti-angiogenesis agent [abstract]. Radiology. 2003;226:37.
71. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist. 2003;9:180-188.
72. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217:377-384.
73. Jacobs AH, Voges J, Kracht LW, et al. Imaging in gene therapy of patients with glioma. J Neurooncol. 2003;65:291-305.
74. Rabinov JD, Lee PL, Barker FG, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology. 2002;225:871-879.
75. Lichy MP, Henze M, Plathow C, et al. Metabolic imaging to follow stereotactic radiation of gliomas - the role of (1)H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. Rofo. 2004;176:1114-1121.
76. Hazle JD, Jackson EF, Schomer DF, et al. Dynamic imaging of intracranial lesions using fast spin-echo imaging: differentiation of brain tumors and treatment effects. J Magn Reson Imaging. 1997;7:1084-1093.
77. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. Am J Neuroradiol. 2000;21:901-909.
78. Tsui EY, Chan JH, Ramsey RG, et al. Late temporal lobe necrosis in patients with nasopharyngeal carcinoma: evaluation with combined multi-section diffusion-weighted and perfusion weighted MR imaging. Eur J Radiol. 2001;39:133-138.
79. Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol. 2005;6:519-530.
80. Newton HB, Snyder MA, Stevens C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas. J Neurooncol. 2002;56:79-86.
81. Newton HB, Snyder MA, Stevens C, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of brain metastases. J Neurooncol. 2003;61:35-44.
82. Newton HB, Figg GM, Slone W, et al. Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. J Neurooncol. 2006;78:157-160.